查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1787906

全球結節性癢疹治療市場分析及預測（至2032年）：依治療類型、給藥途徑、診斷方法、結節性癢疹類型、通路及地區分類

Prurigo Nodularis Treatment Market Forecasts to 2032 - Global Analysis By Treatment Type, Route of Administration, Diagnosis Method, Type of Nodular Prurigo, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球結節性癢疹治療市場預計在 2025 年將達到 22 億美元，到 2032 年將達到 34 億美元，預測期內的複合年成長率為 6.3%。結節性癢疹的治療著重於緩解劇烈搔癢、縮小結節性病變和改善生活品質。治療通常包括局部治療（例如皮質類固醇和止癢膏）、全身生物製藥（例如度普利尤單抗））和照光治療。皮膚科醫生根據嚴重程度和潛在疾病制定治療計劃。對患者進行避免抓撓和維持正確護膚的教育至關重要。定期後續觀察有助於後續觀察並調整治療方法，以長期控制症狀並促進皮膚癒合。

結節性癢疹的盛行率和診斷率不斷上升

結節性癢疹的盛行率不斷上升，尤其是在患有慢性皮膚病和全身性疾病的人群中，是該疾病的主要成長動力。醫療保健提供者和患者意識的提高，使得診斷能夠更早、更準確。皮膚科診療和治療方法工具的普及也進一步推動了這一趨勢。隨著疾病負擔的加重，對有效治療方法的需求也隨之成長，尤其是那些針對潛在免疫機製而非僅僅治療症狀的治療。

最先進治療價格高昂，新興市場獲得治療的機會有限

儘管生物製藥和標靶治療取得了令人鼓舞的進展，但這些治療方法高成本仍然是一個重大障礙。在開發中地區，有限的報銷框架和不均衡的醫療基礎設施限制了患者獲得治療的機會。此外，醫生培訓和對新治療方法認知的差距也阻礙了新療法的推廣。總而言之，這些挑戰減緩了市場滲透，並限制了創新解決方案的普及。

增加對生物目標和小分子療法的研發投入

製藥公司正致力於開發能夠打破搔癢-抓癢循環並調節免疫反應的生物製藥和小分子藥物。突破性療法認定等監管支持正在加速臨床試驗和核准。產學研之間的策略合作也正在拓展治療藥物研發線。這些努力有望帶來更安全、更有效的治療方法，並拓寬市場基礎。

新療法的限制性報銷政策

儘管像杜匹魯單抗和奈莫利珠單抗這樣的生物製藥表現出了強大的療效，但它們的推廣應用卻受到嚴格的報銷政策的限制，尤其是在北美和西歐以外的地區。由於成本高且長期數據有限，付款方仍持謹慎態度。這種經濟不確定性可能會阻礙生物製劑的廣泛應用並減緩創新。如果醫保覆蓋範圍不擴大，許多患者可能會繼續依賴療效較差的傳統療法。

COVID-19的影響：

疫情對結節性癢疹治療市場產生了雙重影響。一方面，供應鏈中斷和皮膚科就診人數減少暫時減緩了治療的普及。另一方面，人們對慢性病的認知提高以及遠距皮膚科的普及促進了遠距會診和護理的連續性。這場危機也加速了數位醫療的普及，使疾病監測和病患參與度得到改善，最終促進了市場的復甦和成長。

預計系統性治療領域將成為預測期內最大的領域

預計系統性治療領域將在預測期內佔據最大市場佔有率，這得益於其在重症和難治性病例中的卓越療效。這些治療方法優於局部用藥，因為它們透過針對發炎途徑提供長期緩解。核准生技藥品的日益普及以及正在進行的新型藥物臨床試驗正在推動該市場的發展。

預計預測期內慢性結節性癢疹的複合年成長率最高。

慢性結節性癢疹預計將在預測期內達到最高成長率。慢性結節性癢疹的特徵是持續性搔癢和抗治療性的結節，需要先進的治療方法。此疾病的致殘性促使患者尋求長期治療方案，從而推動了對生物製藥和免疫調節劑的需求。診斷和認知的提高進一步推動了市場成長。

佔比最大的地區：

由於皮膚病患病率上升、醫療基礎設施不斷擴展以及生物製藥可近性的不斷提高，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度和日本等國家正在推動皮膚病學現代化，並加大對臨床研究的投資，以提高治療效果。政府為促進皮膚健康和早期診斷的措施也為該地區的主導地位做出了貢獻。

複合年成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率，這得益於其先進的醫療基礎設施和生物療法的早期應用。美國在臨床研究方面處於領先地位，目前正在進行大量針對IL-31和IL-4/13抑制劑等新型藥物的臨床試驗，從而重塑治療格局。加拿大雖然在報銷政策方面略顯保守，但正在透過公共衛生計畫和Dupixent等生物製藥的監管核准來擴大其可及性。該地區對慢性病管理和數位皮膚病學平台的關注正在推動市場成長。

免費客製化服務

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球結節性癢疹治療市場（依治療類型）

  • 局部治療
    • 皮質類固醇
    • Calcineurin抑制劑
    • 辣椒素乳膏
    • 潤膚劑/保濕劑
    • 非處方止癢藥
  • 全身性治療
    • 抗組織胺藥
    • 免疫抑制劑
    • 抗驚厥藥/神經病變止痛藥
    • 抗憂鬱症
    • 生物製藥
      • IL-4Ra抑制劑
      • IL-31RA拮抗劑
      • JAK抑制劑
      • 其他生物製藥
    • 鴉片受體拮抗劑
    • 神經激肽1（NK1）受體拮抗劑
    • 口服類固醇
  • 冷凍療法
  • 照光治療
  • 脈衝染料雷射
  • 病灶內注射皮質類固醇
  • 醫用膠帶/封堵器
  • 其他類型的治療

6. 全球結節性癢疹治療市場（依給藥途徑）

  • 局部的
  • 口服
  • 腸外

7. 全球結節性癢疹治療市場（依診斷方法）

  • 皮膚切片檢查
  • 血液檢查
  • 皮膚鏡檢查
  • 其他診斷方法

8.依結節性癢疹類型分類的全球結節性癢疹治療市場

  • 慢性結節性癢疹
  • 急性結節性癢疹
  • 亞急性結節性癢疹

9. 全球結節性癢疹治療市場（依通路）

  • 醫院藥房
  • 零售藥局
  • 網路藥局

10. 全球結節性癢疹治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • AbbVie Inc
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Dermavant Sciences
  • Eli Lilly and Company
  • Galderma
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Leo Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: SMRC30171

According to Stratistics MRC, the Global Prurigo Nodularis Treatment Market is accounted for $2.2 billion in 2025 and is expected to reach $3.4 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Prurigo Nodularis treatment focuses on alleviating intense itching, reducing nodular lesions, and improving quality of life. Management typically involves topical therapies such as corticosteroids and anti-itch creams, systemic medications like immunomodulators or biologics (e.g., dupilumab), and phototherapy. Dermatologists tailor treatment plans based on severity and underlying conditions. Patient education on avoiding scratching and maintaining proper skin care is essential. Regular follow-ups help monitor progress and adjust therapies, aiming for long-term symptom control and skin healing.

Market Dynamics:

Driver:

Rising prevalence and increased diagnosis rates of prurigo nodularis

The increasing incidence of prurigo nodularis, particularly among individuals with chronic dermatological and systemic conditions, is a major growth driver. Enhanced awareness among healthcare providers and patients has led to earlier and more accurate diagnoses. This trend is further supported by improved access to dermatology consultations and diagnostic tools. As the disease burden grows, so does the demand for effective therapies, especially those targeting the underlying immunological mechanisms rather than just symptomatic relief.

Restraint:

High cost of advanced therapies and limited access in emerging markets

Despite promising developments in biologics and targeted treatments, the high cost of these therapies remains a significant barrier. In developing regions, limited reimbursement frameworks and uneven healthcare infrastructure restrict patient access. Additionally, gaps in physician training and awareness about newer treatment modalities further hinder adoption. These challenges collectively slow market penetration and limit the reach of innovative solutions.

Opportunity:

Increasing investment in R&D for targeted biological and small molecule therapies

Pharmaceutical companies are intensifying their focus on developing biologics and small molecule drugs that disrupt the itch-scratch cycle and modulate immune responses. Regulatory support, such as breakthrough therapy designations, is accelerating clinical trials and approvals. Strategic collaborations between industry and academia are also expanding the therapeutic pipeline. These efforts are expected to yield safer, more effective treatments and broaden the market's scope.

Threat:

Limited reimbursement policies for novel therapies

While biologics like dupilumab and nemolizumab show strong efficacy, their adoption is constrained by restrictive reimbursement policies, especially outside North America and Western Europe. Payers remain cautious due to high costs and limited long-term data. This financial uncertainty discourages widespread use and may slow innovation. Without broader insurance coverage, many patients may continue relying on less effective conventional treatments.

Covid-19 Impact:

The pandemic had a dual impact on the prurigo nodularis treatment market. On one hand, supply chain disruptions and reduced dermatology visits temporarily slowed treatment uptake. On the other, heightened awareness of chronic conditions and the expansion of teledermatology encouraged remote consultations and continuity of care. The crisis also accelerated digital health adoption, enabling better disease monitoring and patient engagement, which ultimately supported market recovery and growth

The systemic treatments segment is expected to be the largest during the forecast period

The systemic treatments segment is expected to account for the largest market share during the forecast period due to their superior efficacy in managing severe and refractory cases. These treatments offer long-term relief by targeting inflammatory pathways, making them preferable over topical agents. The growing availability of approved biologics and ongoing clinical trials for novel agents are reinforcing this markets leadership boosting its presence.

The chronic nodular prurigo segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the chronic nodular prurigo segment is predicted to witness the highest growth rate. Chronic nodular prurigo, characterized by persistent, treatment-resistant itch and nodules, demands advanced therapeutic approaches. The debilitating nature of the condition drives patients to seek long-term solutions, boosting demand for biologics and immune modulators. Increased diagnosis and awareness are further fueling the growth of the market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share attributed to rising dermatological disease prevalence, expanding healthcare infrastructure, and growing access to biologic therapies. Countries like China, India, and Japan are investing in dermatology modernization and clinical research, enhancing treatment availability. Government initiatives promoting skin health and early diagnosis are also contributing to regional dominance.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by its advanced healthcare infrastructure and early adoption of biologic therapies. The United States leads in clinical research, with a high volume of ongoing trials for novel agents such as IL-31 and IL-4/13 inhibitors, which are reshaping the therapeutic landscape. Canada, while slightly more conservative in reimbursement policies, is expanding access through public health initiatives and regulatory approvals for biologics like Dupixent. The region's emphasis on chronic disease management and digital dermatology platforms is accelerating market growth.

Key players in the market

Some of the key players in Prurigo Nodularis Treatment Market include AbbVie Inc, Amgen Inc, AstraZeneca, Bayer AG, Dermavant Sciences, Eli Lilly and Company, Galderma, GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson Services, Inc, Leo Pharma, Merck & Co., Inc, Novartis AG, Pfizer Inc, Regeneron Pharmaceuticals, Inc, Sanofi, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, and UCB S.A.

Key Developments:

In June 2025, AbbVie revealed its intention to acquire Capstan Therapeutics to bolster its immunology portfolio, marking another strategic move into next-generation therapies. The deal reflects AbbVie's ongoing commitment to expanding its presence in autoimmune and inflammatory diseases.

In May 2025, Regeneron agreed to acquire genetic testing company 23andMe following its bankruptcy filing, securing its personal genome service and health-research assets. The deal set to close in Q3 2025 retains all staff and establishes an independent privacy ombudsman to oversee consumer data protections

In April 2025, Regeneron announced a long-term partnership worth over $3 billion with Fujifilm Diosynth Biotechnologies to nearly double its biologics production capacity at Holly Springs, NC, and expand manufacturing footprint nationwide.

Treatment Types Covered:

  • Topical Treatments
  • Systemic Treatments
  • Cryotherapy
  • Phototherapy
  • Pulsed Dye Laser
  • Intralesional Corticosteroid Injections
  • Medical Tape/Occlusion
  • Other Treatment Types

Route of Administrations Covered:

  • Topical
  • Oral
  • Parenteral

Diagnosis Methods Covered:

  • Skin Biopsy
  • Blood Tests
  • Dermoscopy
  • Other Diagnosis Methods

Type of Nodular Prurigos Covered:

  • Chronic Nodular Prurigo
  • Acute Nodular Prurigo
  • Subacute Nodular Prurigo

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Prurigo Nodularis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Topical Treatments
    • 5.2.1 Corticosteroids
    • 5.2.2 Calcineurin Inhibitors
    • 5.2.3 Capsaicin Cream
    • 5.2.4 Emollients/Moisturizers
    • 5.2.5 Non-prescription Itch Relief
  • 5.3 Systemic Treatments
    • 5.3.1 Antihistamines
    • 5.3.2 Immunosuppressants
    • 5.3.3 Anticonvulsants/Neuropathic Pain Medications
    • 5.3.4 Antidepressants
    • 5.3.5 Biologics
      • 5.3.5.1 IL-4Ra inhibitors
      • 5.3.5.2 IL-31RA antagonists
      • 5.3.5.3 JAK Inhibitors
      • 5.3.5.4 Other Biologics
    • 5.3.6 Opioid Receptor Antagonists
    • 5.3.7 Neurokinin 1 (NK1) Receptor Antagonists
    • 5.3.8 Oral Corticosteroids
  • 5.4 Cryotherapy
  • 5.5 Phototherapy
  • 5.6 Pulsed Dye Laser
  • 5.7 Intralesional Corticosteroid Injections
  • 5.8 Medical Tape/Occlusion
  • 5.9 Other Treatment Types

6 Global Prurigo Nodularis Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Topical
  • 6.3 Oral
  • 6.4 Parenteral

7 Global Prurigo Nodularis Treatment Market, By Diagnosis Method

  • 7.1 Introduction
  • 7.2 Skin Biopsy
  • 7.3 Blood Tests
  • 7.4 Dermoscopy
  • 7.5 Other Diagnosis Methods

8 Global Prurigo Nodularis Treatment Market, By Type of Nodular Prurigo

  • 8.1 Introduction
  • 8.2 Chronic Nodular Prurigo
  • 8.3 Acute Nodular Prurigo
  • 8.4 Subacute Nodular Prurigo

9 Global Prurigo Nodularis Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Prurigo Nodularis Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc
  • 12.2 Amgen Inc.
  • 12.3 AstraZeneca
  • 12.4 Bayer AG
  • 12.5 Dermavant Sciences
  • 12.6 Eli Lilly and Company
  • 12.7 Galderma
  • 12.8 GlaxoSmithKline plc
  • 12.9 Incyte Corporation
  • 12.10 Johnson & Johnson Services, Inc.
  • 12.11 Leo Pharma
  • 12.12 Merck & Co., Inc.
  • 12.13 Novartis AG
  • 12.14 Pfizer Inc.
  • 12.15 Regeneron Pharmaceuticals, Inc.
  • 12.16 Sanofi
  • 12.17 Takeda Pharmaceutical Company Limited
  • 12.18 Teva Pharmaceutical Industries Ltd.
  • 12.19 UCB S.A.

List of Tables

  • Table 1 Global Prurigo Nodularis Treatment Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Prurigo Nodularis Treatment Market Outlook, By Treatment Type (2024-2032) ($MN)
  • Table 3 Global Prurigo Nodularis Treatment Market Outlook, By Topical Treatments (2024-2032) ($MN)
  • Table 4 Global Prurigo Nodularis Treatment Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 5 Global Prurigo Nodularis Treatment Market Outlook, By Calcineurin Inhibitors (2024-2032) ($MN)
  • Table 6 Global Prurigo Nodularis Treatment Market Outlook, By Capsaicin Cream (2024-2032) ($MN)
  • Table 7 Global Prurigo Nodularis Treatment Market Outlook, By Emollients/Moisturizers (2024-2032) ($MN)
  • Table 8 Global Prurigo Nodularis Treatment Market Outlook, By Non-prescription Itch Relief (2024-2032) ($MN)
  • Table 9 Global Prurigo Nodularis Treatment Market Outlook, By Systemic Treatments (2024-2032) ($MN)
  • Table 10 Global Prurigo Nodularis Treatment Market Outlook, By Antihistamines (2024-2032) ($MN)
  • Table 11 Global Prurigo Nodularis Treatment Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 12 Global Prurigo Nodularis Treatment Market Outlook, By Anticonvulsants/Neuropathic Pain Medications (2024-2032) ($MN)
  • Table 13 Global Prurigo Nodularis Treatment Market Outlook, By Antidepressants (2024-2032) ($MN)
  • Table 14 Global Prurigo Nodularis Treatment Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 15 Global Prurigo Nodularis Treatment Market Outlook, By IL-4Ra inhibitors (2024-2032) ($MN)
  • Table 16 Global Prurigo Nodularis Treatment Market Outlook, By IL-31RA antagonists (2024-2032) ($MN)
  • Table 17 Global Prurigo Nodularis Treatment Market Outlook, By JAK Inhibitors (2024-2032) ($MN)
  • Table 18 Global Prurigo Nodularis Treatment Market Outlook, By Other Biologics (2024-2032) ($MN)
  • Table 19 Global Prurigo Nodularis Treatment Market Outlook, By Opioid Receptor Antagonists (2024-2032) ($MN)
  • Table 20 Global Prurigo Nodularis Treatment Market Outlook, By Neurokinin 1 (NK1) Receptor Antagonists (2024-2032) ($MN)
  • Table 21 Global Prurigo Nodularis Treatment Market Outlook, By Oral Corticosteroids (2024-2032) ($MN)
  • Table 22 Global Prurigo Nodularis Treatment Market Outlook, By Cryotherapy (2024-2032) ($MN)
  • Table 23 Global Prurigo Nodularis Treatment Market Outlook, By Phototherapy (2024-2032) ($MN)
  • Table 24 Global Prurigo Nodularis Treatment Market Outlook, By Pulsed Dye Laser (2024-2032) ($MN)
  • Table 25 Global Prurigo Nodularis Treatment Market Outlook, By Intralesional Corticosteroid Injections (2024-2032) ($MN)
  • Table 26 Global Prurigo Nodularis Treatment Market Outlook, By Medical Tape/Occlusion (2024-2032) ($MN)
  • Table 27 Global Prurigo Nodularis Treatment Market Outlook, By Other Treatment Types (2024-2032) ($MN)
  • Table 28 Global Prurigo Nodularis Treatment Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 29 Global Prurigo Nodularis Treatment Market Outlook, By Topical (2024-2032) ($MN)
  • Table 30 Global Prurigo Nodularis Treatment Market Outlook, By Oral (2024-2032) ($MN)
  • Table 31 Global Prurigo Nodularis Treatment Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 32 Global Prurigo Nodularis Treatment Market Outlook, By Diagnosis Method (2024-2032) ($MN)
  • Table 33 Global Prurigo Nodularis Treatment Market Outlook, By Skin Biopsy (2024-2032) ($MN)
  • Table 34 Global Prurigo Nodularis Treatment Market Outlook, By Blood Tests (2024-2032) ($MN)
  • Table 35 Global Prurigo Nodularis Treatment Market Outlook, By Dermoscopy (2024-2032) ($MN)
  • Table 36 Global Prurigo Nodularis Treatment Market Outlook, By Other Diagnosis Methods (2024-2032) ($MN)
  • Table 37 Global Prurigo Nodularis Treatment Market Outlook, By Type of Nodular Prurigo (2024-2032) ($MN)
  • Table 38 Global Prurigo Nodularis Treatment Market Outlook, By Chronic Nodular Prurigo (2024-2032) ($MN)
  • Table 39 Global Prurigo Nodularis Treatment Market Outlook, By Acute Nodular Prurigo (2024-2032) ($MN)
  • Table 40 Global Prurigo Nodularis Treatment Market Outlook, By Subacute Nodular Prurigo (2024-2032) ($MN)
  • Table 41 Global Prurigo Nodularis Treatment Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 42 Global Prurigo Nodularis Treatment Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 43 Global Prurigo Nodularis Treatment Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 44 Global Prurigo Nodularis Treatment Market Outlook, By Online Pharmacies (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.